M. Alexander Otto, PA, MMS July 20, 2023 The US Food and Drug Administration today approved quizartinib (Vanflyta) for adults with acute myeloid leukemia (AML) that carries the FLT3-ITD genetic mutation. The FDA also approved the LeukoStrat CDx FLT3 Mutation Assay to determine whether patients have this mutation. The agency granted quizartinib a first-line indication for use in combination with standard chemotherapy — cytarabine and...